Short‑term use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice

Yu,Qi; Wang,Fang; Meng,Xiaodong; Gong,Yiren; Wang,Yanli; Xu,Cangbao; Wang,Siwang

doi:10.3892/mmr.2018.9239

Short‑term use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice

Authors:
- Qi Yu
- Fang Wang
- Xiaodong Meng
- Yiren Gong
- Yanli Wang
- Cangbao Xu
- Siwang Wang
View Affiliations

Affiliations: Institute of Material Medical, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases and Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, Shaanxi 710021, P.R. China
Published online on: July 3, 2018 https://doi.org/10.3892/mmr.2018.9239
Pages: 2780-2788
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Low‑density lipoprotein receptors (LDLRs) may serve a role in the diabetogenic effect of statins; however, the effects of statins on LDLR expression and its regulation in the pancreas and islets have yet to be determined. To exclude the long‑term effects of treatment with atorvastatin, which allows mice to adapt, male C57BL/j and apolipoprotein E‑deficient mice were acutely treated with oral atorvastatin for 6 weeks, and glucose homeostasis and LDLR expression in the pancreas and islets were examined. In the present study, it was observed that the short‑term use of atorvastatin affected insulin sensitivity in normal mice and glucose tolerance in hyperlipidemic mice. Furthermore, it was identified that 6 weeks of treatment with atorvastatin suppressed LDLR expression in the pancreas and pancreatic islets in C57BL/j mice, and an increase in proprotein convertase subtilisin/kexin type 9 expression was additionally observed in the pancreas. However, 6 weeks of treatment with atorvastatin did not affect LDLR expression in the pancreas of hyperlipidemic mice. It may be concluded that the short‑term use of atorvastatin disturbs glucose homeostasis and suppresses LDLR expression in the pancreas and pancreatic islets in C57BL/j mice, suggesting that the role of LDLR in the diabetogenic effect of statins requires further investigation.

View Figures

View References

1	Brault M, Ray J, Gomez YH, Mantzoros CS and Daskalopoulou SS: Statin treatment and new-onset diabetes: A review of proposed mechanisms. Metabolism. 63:735–745. 2014. View Article : Google Scholar : PubMed/NCBI
2	Yu Q, Chen Y and Xu CB: Statins and new-onset diabetes mellitus: LDL receptor may provide a key link. Front Pharmacol. 8:3722017. View Article : Google Scholar : PubMed/NCBI
3	Besseling J, Kastelein JJ, Defesche JC, Hutten BA and Hovingh GK: Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. 313:1029–1036. 2015. View Article : Google Scholar : PubMed/NCBI
4	Yu Q, Su X and Liu E: Could familial hypercholesterolemia oppose the diabetogenic effect of statin? Comments on a new SAFEHEART study. Int J Cardiol. 202:954–955. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ishikawa M, Iwasaki Y, Yatoh S, Kato T, Kumadaki S, Inoue N, Yamamoto T, Matsuzaka T, Nakagawa Y, Yahagi N, et al: Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: A new model for lipotoxicity. J Lipid Res. 49:2524–2534. 2008. View Article : Google Scholar : PubMed/NCBI
6	Brunham LR, Kruit JK, Verchere CB and Hayden MR: Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest. 118:403–408. 2008. View Article : Google Scholar : PubMed/NCBI
7	Cheng D, Wang Y, Gao S, Wang X, Sun W, Bai L, Cheng G, Chu Y, Zhao S and Liu E: Atorvastatin delays the glucose clearance rate in hypercholesterolemic rabbits. Biomed Pharmacother. 72:24–29. 2015. View Article : Google Scholar : PubMed/NCBI
8	Capel F, Chabrier G, Pitois E, Rigaudière JP, Le Plenier S, Durand C, Jouve C, de Bandt JP, Cynober L and Moinard C: Combining citrulline with atorvastatin preserves glucose homeostasis in a murine model of diet-induced obesity. Br J Pharmacol. 172:4996–5008. 2015. View Article : Google Scholar : PubMed/NCBI
9	Liang J, Yin K, Cao X, Han Z, Huang Q, Zhang L, Ma W, Ding F, Bi C, Feng D, et al: Attenuation of low ambient temperature-induced myocardial hypertrophy by atorvastatin via promoting Bcl-2 expression. Cell Physiol Biochem. 41:286–295. 2017. View Article : Google Scholar : PubMed/NCBI
10	Ren XM, Zuo GF, Wu W, Luo J, Ye P, Chen SL and Hu ZY: Atorvastatin alleviates experimental diabetic cardiomyopathy by regulating the GSK-3β-PP2Ac-NF-κB signaling axis. PLoS One. 11:e01667402016. View Article : Google Scholar : PubMed/NCBI
11	Wu W, Zhao L, Yang P, Zhou W, Li B, Moorhead JF, Varghese Z, Ruan XZ and Chen Y: Inflammatory stress sensitizes the liver to atorvastatin-induced injury in ApoE−/−mice. PLoS One. 11:e01595122016. View Article : Google Scholar : PubMed/NCBI
12	Lee S, Lee Y, Kim J, An J and Kim K, Lee H, Kong H, Song Y and Kim K: Atorvastatin and rosuvastatin improve physiological parameters and alleviate immune dysfunction in metabolic disorders. Biochem Biophys Res Commun. 478:1242–1247. 2016. View Article : Google Scholar : PubMed/NCBI
13	Roth L, Rombouts M, Schrijvers DM, Martinet W and De Meyer GR: Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture. Vascul Pharmacol. 80:50–58. 2016. View Article : Google Scholar : PubMed/NCBI
14	Han H, Chen Y, Zhu J, Ni J, Sun J and Zhang R: Atorvastatin attenuates p-cresyl sulfate-induced atherogenesis and plaque instability in ApoE knockout mice. Mol Med Rep. 14:3122–3128. 2016. View Article : Google Scholar : PubMed/NCBI
15	Bruder-Nascimento T, Callera GE, Montezano AC, He Y, Antunes TT, Cat Nguyen Dinh A, Tostes RC and Touyz RM: Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: Role of Rac1/2-sensitive Nox-dependent pathways. Clin Sci (Lond). 128:411–423. 2015. View Article : Google Scholar : PubMed/NCBI
16	Park SH, Sung YY, Nho KJ and Kim HK: Protective activity ethanol extract of the fruits of Illicium verum against atherogenesis in apolipoprotein E knockout mice. BMC Complement Altern Med. 15:2322015. View Article : Google Scholar : PubMed/NCBI
17	van den Hoek AM, van der Hoorn JW, Maas AC, van den Hoogen RM, van Nieuwkoop A, Droog S, Offerman EH, Pieterman EJ, Havekes LM and Princen HM: APOE*3Leiden. CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes Obes Metab. 16:537–544. 2014. View Article : Google Scholar : PubMed/NCBI
18	Yu Q, Liu Z, Waqar AB, Ning B, Yang X, Shiomi M, Graham MJ, Crooke RM, Liu E, Dong S and Fan J: Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits. Mediators Inflamm. 2014:9791322014. View Article : Google Scholar : PubMed/NCBI
19	Yu Q, Wang Y, Yu Y, Li Y, Zhao S, Chen Y, Waqar AB, Fan J and Liu E: Expression of TRPV1 in rabbits and consuming hot pepper affects its body weight. Mol Biol Rep. 39:7583–7589. 2012. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Li DS, Yuan YH, Tu HJ, Liang QL and Dai LJ: A protocol for islet isolation from mouse pancreas. Nat Protoc. 4:1649–1652. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhao W and Zhao SP: Different effects of statins on induction of diabetes mellitus: An experimental study. Drug Des Devel Ther. 9:6211–6223. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jensen EC: Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec (Hoboken). 296:378–381. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ansar S, Koska J and Reaven PD: Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: Focus on incretins. Cardiovasc Diabetol. 10:612011. View Article : Google Scholar : PubMed/NCBI
25	Bot I, Jukema JW, Lankhuizen IM, van Berkel TJ and Biessen EA: Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Atherosclerosis. 214:295–300. 2011. View Article : Google Scholar : PubMed/NCBI
26	Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, et al: HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res. 116:1133–1142. 2015. View Article : Google Scholar : PubMed/NCBI
27	Goldstein JL and Brown MS: A century of cholesterol and coronaries: From plaques to genes to statins. Cell. 161:161–172. 2015. View Article : Google Scholar : PubMed/NCBI
28	Axsom K, Berger JS and Schwartzbard AZ: Statins and diabetes: The good, the bad and the unknown. Curr Atheroscler Rep. 15:2992013. View Article : Google Scholar : PubMed/NCBI
29	Hennekens CH, Teng B and Pfeffer MA: Statins and diabetes: Current perspectives and implications for clinicians. Am J Med. 130:504–506. 2017. View Article : Google Scholar : PubMed/NCBI
30	Sattar N and Taskinen MR: Statins are diabetogenic-myth or reality? Atheroscler Suppl. 13:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
31	Furman BL: Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 70:5.47.1–20. 2015. View Article : Google Scholar
32	Hong C, Marshall SM, McDaniel AL, Graham M, Layne JD, Cai L, Scotti E, Boyadjian R, Kim J, Chamberlain BT, et al: The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice. Cell Metab. 20:910–918. 2014. View Article : Google Scholar : PubMed/NCBI
33	Attie AD and Seidah NG: Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab. 1:290–292. 2005. View Article : Google Scholar : PubMed/NCBI
34	Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Brunham LR, Verchere CB and Hayden MR: Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia. 53:1110–1119. 2010. View Article : Google Scholar : PubMed/NCBI